Gut Microbiome in Sepsis

被引:16
作者
Klingensmith, Nathan J. [1 ]
Coopersmith, Craig M. [2 ,3 ,4 ,5 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA USA
[2] Emory Univ, Sch Med, Dept Surg, Atlanta, GA USA
[3] Emory Univ, Emory Crit Care Ctr, Sch Med, Atlanta, GA USA
[4] Emory Univ, Sch Med, Dept Surg, 101 Woodruff Circle Suite WMB 5105, Atlanta, GA 30322 USA
[5] Emory Univ, Sch Med, Emory Crit Care Ctr, 101 Woodruff Circle Suite WMB 5105, Atlanta, GA 30322 USA
基金
美国国家卫生研究院;
关键词
gut; intestine; microbiome; pathobiome; probiotics; sepsis; CHAIN FATTY-ACIDS; EPITHELIAL APOPTOSIS; IMMUNE-RESPONSES; BARRIER FUNCTION; IGA RESPONSES; PROBIOTICS; HEALTH; BACTERIAL; SURVIVAL; CELLS;
D O I
10.1089/sur.2022.420
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The gut has been hypothesized to be the "motor" of multiple organ dysfunction in sepsis. Although there are multiple ways in which the gut can drive systemic inflammation, increasing evidence suggests that the intestinal microbiome plays a more substantial role than previously appreciated. An English language literature review was performed to summarize the current knowledge of sepsis-induced gut microbiome dysbiosis. Conversion of a normal microbiome to a pathobiome in the setting of sepsis is associated with worsened mortality. Changes in microbiome composition and diversity signal the intestinal epithelium and immune system resulting in increased intestinal permeability and a dysregulated immune response to sepsis. Clinical approaches to return to microbiome homeostasis may be theoretically possible through a variety of methods including probiotics, prebiotics, fecal microbial transplant, and selective decontamination of the digestive tract. However, more research is required to determine the efficacy (if any) of targeting the microbiome for therapeutic gain. The gut microbiome rapidly loses diversity with emergence of virulent bacteria in sepsis. Restoring normal commensal bacterial diversity through various therapies may be an avenue to improve sepsis mortality.
引用
收藏
页码:250 / 257
页数:8
相关论文
共 88 条
[1]   Pseudomonas aeruginosa Virulence Expression Is Directly Activated by Morphine and Is Capable of Causing Lethal Gut-Derived Sepsis in Mice During Chronic Morphine Administration [J].
Babrowski, Trissa ;
Holbrook, Christopher ;
Moss, Jonathan ;
Gottlieb, Lawrence ;
Valuckaite, Vesta ;
Zaborin, Alexander ;
Poroyko, Valeriy ;
Liu, Donald C. ;
Zaborina, Olga ;
Alverdy, John C. .
ANNALS OF SURGERY, 2012, 255 (02) :386-393
[2]   IgA Responses to Microbiota [J].
Bunker, Jeffrey J. ;
Bendelac, Albert .
IMMUNITY, 2018, 49 (02) :211-224
[3]   Enteric immunity, the gut microbiome, and sepsis: Rethinking the germ theory of disease [J].
Cabrera-Perez, Javier ;
Badovinac, Vladimir P. ;
Griffith, Thomas S. .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2017, 242 (02) :127-139
[4]   Safety of using enteral nutrition formulations containing dietary fiber in hospitalized critical care patients: A systematic review and meta-analysis [J].
Cara, Kelly Copeland ;
Beauchesne, Andrew R. ;
Wallace, Taylor C. ;
Chung, Mei .
JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2021, 45 (05) :882-906
[5]  
CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196
[6]   Intestinal crosstalk: A new paradigm for understanding the gut as the "motor" of critical illness [J].
Clark, Jessica A. ;
Coopersmith, Craig M. .
SHOCK, 2007, 28 (04) :384-393
[7]   Finishing the euchromatic sequence of the human genome [J].
Collins, FS ;
Lander, ES ;
Rogers, J ;
Waterston, RH .
NATURE, 2004, 431 (7011) :931-945
[8]   Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice [J].
Coopersmith, CM ;
Chang, KC ;
Swanson, PE ;
Tinsley, KW ;
Stromberg, PE ;
Buchman, TG ;
Karl, IE ;
Hotchkiss, RS .
CRITICAL CARE MEDICINE, 2002, 30 (01) :195-201
[9]   Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis [J].
Coopersmith, CM ;
Stromberg, PE ;
Dunne, WM ;
Davis, CG ;
Amiot, DM ;
Buchman, TG ;
Karl, IE ;
Hotchkiss, RS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1716-1721
[10]   Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial [J].
Cornely, Oliver A. ;
Crook, Derrick W. ;
Esposito, Roberto ;
Poirier, Andre ;
Somero, Michael S. ;
Weiss, Karl ;
Sears, Pamela ;
Gorbach, Sherwood .
LANCET INFECTIOUS DISEASES, 2012, 12 (04) :281-289